RECCE PHARMACEUTICALS LTD — Director's Dealing 2019

Feb 14, 2019

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Recce Pharmaceuticals Ltd
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Dr John Prendergast

Date of last notice 27 April 2018

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances givingrise to the relevant interest.	N/A
Date of change	15/02/2019
No. of securities held prior to change	Nil
Class	Fully paid ordinary shares
Number acquired	250,000 fully paid ordinary shares
Number disposed	Nil
Value/ConsiderationNote: If consideration is non-cash, provide detailsand estimated valuation	Nil cash consideration. The 250,000 fully paid ordinaryshares are being issued as part of Dr Prendergast’sremuneration, as approved by shareholders at the AnnualGeneral Meeting on 29 November 2018.

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	No. of securities held after change	250,000 fully paid ordinary shares
Nature of change		Issue of 250,000 fully paid ordinary shares, as approved
Example:on-markettrade,off-marketexercise of options, issue of securitiesdividend reinvestment plan, participation	trade,underin buy-	by shareholders at the Annual General Meeting on 29November 2018.
back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which	N/A
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change	N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

If prior written clearance was provided, on what date was N/A this provided?

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3